ARNA Related Upgrades
-
UPDATE: JPMorgan Upgrades Orexigen Therapeutics (OREX) to Overweight, Best Opportunity in Obesity Space
-
Piper Jaffray Upgrades Arena Pharma (ARNA) to Overweight
-
Leerink Swann Upgrades Arena Pharma (ARNA) to Outperform; Positive Panel Vote For Lorcaserin
-
Jefferies Upgrades Arena Pharma (ARNA) to Buy
-
BMO Capital Upgrades Arena Pharma (ARNA) to Outperform, Raises Target 600%
-
Piper Jaffray Upgrades Arena Pharma (ARNA) to Overweight
-
Summer Street Upgrades Arena Pharma (ARNA) to Neutral; Some Clarity From This Week’s FDA Meeting
-
Arena Pharmaceuticals (ARNA): Upgraded to Overweight at J.P. Morgan
-
J.P. Morgan on Biotechnology and Drugs Stocks; Upgrades ARNA, Cuts VVUS
-
Leerink Swann Upgrades Arena Pharmaceuticals (ARNA) to Outperform; Lorcaserin U.S. Partnership Announced
-
Rodman & Renshaw Upgrades Arena Pharmaceutical (ARNA) to Market Perform
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
BofA Upgrades Arena Pharmaceuticals (ARNA) to Buy
-
AG Edwards upgrades Arena Pharma (ARNA) to Buy
-
CIBC upgrades ARNA to Outperform
Back to ARNA Stock Lookup
